How effective is Gleevec for Cancer? (a real world drug study)
Summary:
Overall ratings: 4.2/5 Long term ratings: 4.5/5
This is a phase IV clinical study of how effective Gleevec (imatinib mesylate) is for Cancer and for what kind of people. The study is created by eHealthMe from 6 Gleevec users and is updated continuously.
What is Gleevec?
Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 35,415 Gleevec users. Check the latest studies of Gleevec.
What is Cancer?
Cancer: no further information found. Check the latest studies of Cancer.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
6 people are studied for taking Gleevec in Cancer
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Gleevec effectiveness for Cancer (number of people):
Overall:
- not at all: 0
- somewhat: 0
- moderate: 1
- high: 3
- very high: 2
Long Term:
- not at all: 0
- somewhat: 0
- moderate: 0
- high: 2
- very high: 2
Gender of people who take Gleevec for Cancer *:
- female: 66.67 %
- male: 33.33 %
Age of people who take Gleevec for Cancer *:
- 0-1: 0.0 %
- 2-9: 16.67 %
- 10-19: 16.67 %
- 20-29: 0.0 %
- 30-39: 16.67 %
- 40-49: 16.67 %
- 50-59: 0.0 %
- 60+: 33.33 %
Who find Gleevec more effective for Cancer?
Gender of people who take Gleevec for Cancer *:
- female: 80 %
- male: 20 %
Age of people who take Gleevec for Cancer *:
- 0-1: 0.0 %
- 2-9: 20 %
- 10-19: 20 %
- 20-29: 0.0 %
- 30-39: 20 %
- 40-49: 20 %
- 50-59: 0.0 %
- 60+: 20 %
* Approximation only. Some reports may have incomplete information.
Do you take Gleevec?
- You can start a phase IV clinical trial to monitor Gleevec safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- Lin SC, Su YC, Huang YS, Lee CC, "Zolpidem increased cancer risk in patients with sleep disorder: A 3-year follow-up study", Journal of Medical Sciences, 2016 Mar .
- Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
- Lin SC, Su YC, Huang YS, Lee CC, "Zolpidem increased cancer risk in patients with sleep disorder: A 3-year follow-up study", Journal of Medical Sciences, 2016 Mar .
- Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
Related studies
Alternative drugs to, pros and cons of:
- Gleevec (35,415 reports)
Treatments, associated drugs and conditions:
- Cancer (727 reports)
How the study uses the data?
The study is based on imatinib mesylate (the active ingredients of Gleevec) and Gleevec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Ipratropium Bromide and Infection - Ear for Women aged 60+ - 10 seconds ago
- Ipratropium Bromide and Ear Infection for Women aged 60+ - 11 seconds ago
- Ipratropium Bromide and Otitis for Women aged 60+ - 11 seconds ago
- Could Invokana cause Muscle Atrophy? - 11 seconds ago
- Could Morphine Sulfate cause Adverse Event? - 11 seconds ago
- Could Valsartan cause Sleep Apnea Syndrome? - 12 seconds ago
- Progesterone vs. Mono-Linyah, side effect and effectiveness comparison - 15 seconds ago
- Wellbutrin Sr vs. Pexeva, side effect and effectiveness comparison - 16 seconds ago
- Enlarged Prostate and drugs of ingredients of gabapentin - 19 seconds ago
- Vigamox and Vomiting for Women aged 60+ - 22 seconds ago